shadow_tr
.
Nov 2014
Su Mo Tu We Th Fr Sa
      1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
      
Quick Search


GUEST SERVICES



.

Department of Pharmacology Fall Seminar Series

Inflammation in Diabetes and Prediabetes - a target for pharmacological intervention?

featuring Vivian A. Fonseca, MD, FRCP

Date: Friday, November 1, 2013
Time: 12:00 PM - 1:00 PM
Building: 1430 Tulane Avenue (Medicine) in Room 4700
Location: downtown campus

Biography

Dr. Fonseca serves on the clinical practice committee of the American Diabetes Association (current chairman) and the joint ADA/ACC “Make the Link” Program. He is the President of Medicine & Science for the American Diabetes Association

He is editor-in-chief of Diabetes Care since 2007, having formerly been associate editor. He was until 2006 editor-in-chief of the Journal of the Metabolic Syndrome and related disorders. He served on the editorial board of the Journal of Clinical Endocrinology and Metabolism (2003-2006). He is an ad hoc reviewer for several other journals including New England Journal of Medicine,JAMA, Diabetes, Diabetic Medicine, Kidney International, the American Journal of Clinical Nutrition, the British Medical Journal, and Metabolism.

Dr. Fonseca is a fellow of the American Association of Clinical Endocrinologists, the Royal College of Physicians ( London), and the American College of Physicians. He is a member of the Endocrine Society, the American Diabetes Association, and the International Diabetes Federation. He serves on several national and international committees, and has published over 200 papers, review articles and book chapters.

Research Interests

Dr. Fonseca's current research interests include the prevention and treatment of diabetic complications and risk factor reduction in cardiovascular disease. He has a research program evaluating homocysteine and inflammation as risk factors for heart disease in diabetes. He is currently the principal investigator of the DRMS (diabetes remote management system) study, a study aimed at evaluating the effectiveness and possibilities of using a remote technology system to enhance and manage daily care for patients with Type 2 Diabetes Mellitus. Dr. Fonseca is also the principal investigator of the Zemplar study, a study investigating the effects of Zemplar (paricalcitol) on endothelial function and inflammation in patients with Type 2 Diabetes Mellitus and stage 3 or 4 chronic kidney disease.

He is also the principal investigator of the ACCORDION study, an NIH sponsored, multicenter follow –up study to the ACCORD study which examined cardiovascular risk and diabetes. Dr. Fonseca is also the principal investigator for the BEACON study, a multicenter study evaluating the effects of bardoxolone methyl in patients with chronic kidney disease and Type 2 diabetes. Dr. Fonseca has lectured in the United States and abroad, and his publications include more than 180 articles. He is the editor of the text book "Clinical Diabetes: Translating Research into Practice" (El Sevier 2006) and several monographs and book chapters.

For more information on Dr. Fonseca, please click the link here.

Sponsored by: Pharmacology Department

Admission: Admission is charged
Attendance: Tulane community
Open to: Alumni, Faculty, Graduate students, Undergraduates, Visitors

For more information contact Sewann Strong via email to sstrong@tulane.edu or by phone at 504-988-5444






Follow Tulane sponsored and related events on Twitter at http://twitter.com/#!/TulaneEvents

Calendar of Events, Tulane University  504-865-5000 calendar@tulane.edu